Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Marek

Showing results (61-70 of 144) with videos related to

Pageof 15
Sort By:
The Lancet. Neurology|June 4, 2013
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trialAnthony H V Schapira, Michael P McDermott, Paolo Barone, et al.
Ebiomedicine|February 2, 2025
Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional studyKenneth Marek, David S Russell, Luis Concha-Marambio, et al.
NPJ Parkinson'S Disease|August 13, 2025
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trialsGennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 6, 2018
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's diseaseChristos Koros, Athina Simitsi, Andreas Prentakis, et al.
NPJ Parkinson'S Disease|July 2, 2025
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trialsGennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
Plos One|June 13, 2017
A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's diseaseBoris Hayete, Diane Wuest, Jason Laramie, et al.
Molecular Imaging and Biology|August 8, 2018
Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET TracersCristian C Constantinescu, Cedric Tresse, MingQiang Zheng, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 15, 2012
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's diseaseBernard Ravina, Kenneth Marek, Shirley Eberly, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2017
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trialsAdam S Fleisher, Abhinay D Joshi, Karen L Sundell, et al.
Neurology|February 6, 2025
α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson DiseaseDavid G Coughlin, Ben Shifflett, Carly M Farris, et al.
Pageof 15

Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
The Lancet. Neurology|June 4, 2013
Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trialAnthony H V Schapira, Michael P McDermott, Paolo Barone, et al.
Ebiomedicine|February 2, 2025
Evidence for alpha-synuclein aggregation in older individuals with hyposmia: a cross-sectional studyKenneth Marek, David S Russell, Luis Concha-Marambio, et al.
NPJ Parkinson'S Disease|August 13, 2025
Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trialsGennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|October 6, 2018
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's diseaseChristos Koros, Athina Simitsi, Andreas Prentakis, et al.
NPJ Parkinson'S Disease|July 2, 2025
Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trialsGennaro Pagano, Dylan Trundell, Tanya Simuni, et al.
Plos One|June 13, 2017
A Bayesian mathematical model of motor and cognitive outcomes in Parkinson's diseaseBoris Hayete, Diane Wuest, Jason Laramie, et al.
Molecular Imaging and Biology|August 8, 2018
Development and In Vivo Preclinical Imaging of Fluorine-18-Labeled Synaptic Vesicle Protein 2A (SV2A) PET TracersCristian C Constantinescu, Cedric Tresse, MingQiang Zheng, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|September 15, 2012
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's diseaseBernard Ravina, Kenneth Marek, Shirley Eberly, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2017
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trialsAdam S Fleisher, Abhinay D Joshi, Karen L Sundell, et al.
Neurology|February 6, 2025
α-Synuclein Seed Amplification Assay Amplification Parameters and the Risk of Progression in Prodromal Parkinson DiseaseDavid G Coughlin, Ben Shifflett, Carly M Farris, et al.
Pageof 15